Compare · DXCM vs VTAK
DXCM vs VTAK
Side-by-side comparison of DexCom Inc. (DXCM) and Catheter Precision Inc. (VTAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and VTAK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $40.07B.
- Over the past year, DXCM is down 13.5% and VTAK is down 83.7% - DXCM leads by 70.2 points.
- VTAK has been more active in the news (8 items in the past 4 weeks vs 4 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for VTAK).
- Company
- DexCom Inc.
- Catheter Precision Inc.
- Price
- $61.55-1.84%
- $0.90-3.09%
- Market cap
- $40.07B
- -
- 1M return
- -7.89%
- -22.71%
- 1Y return
- -13.51%
- -83.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- 2018
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest VTAK
- Catheter Precision Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy
- FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
- VTAK Definitive Agreement to Acquire 100% of Fly Flyte Inc. Obtains Shareholder Approval
- Catheter Precision Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Catheter Precision Announces Accepted Publication in Leading European Medical Journal
- Catheter Precision to Attend the Annual European Heart Rhythm Association Conference
- New LockeT Data Accepted in Leading Electrophysiology Journal
- Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Catheter Precision Inc.